Operating identity
The website and checked reports identify ABN 14 754 514 569. ABN Lookup lists the Trustee for Ozcanium Unit Trust and the Ozcanium Analytics business name. Ibrahim A. Ozcan signs the reports as lead chemist. Sydney is the published service location; a laboratory street address was not confirmed in the reviewed service pages.
Operating history and strongest evidence
Two issuer-confirmed, complete two-page September 24, 2026 reports name the client and analyst and expose both chromatographic results and separate mass-based identity evidence.
Accreditation scope
NATA's active-organisation search for Ozcanium returned zero results on October 9, 2026. The reviewed website and reports supplied no ISO/IEC 17025 accreditation number or peptide method scope.
Methods and intake
The service accepts sample orders online, subject to method suitability. It advertises UPLC purity, LC-MS/MS identity, calibrated content, optional endotoxin and same-batch vial comparisons. Its current peptide page estimates 4–10 business days after payment, receipt and intake checks.
Public service record
Supplier libraries and a Peptide Hub Australia repeat-customer account show use beyond the two checked Ultima samples. That account describes improved communication and turnaround after an initial delay. No audited customer aggregate or controlled interlaboratory proficiency series was established.
Important limits
The checked PDFs do not include a quantitative calibration curve, reference-standard certificate, measurement uncertainty, complete acquisition method or independent proficiency results. This review inspected registry records, public documentation and retained issuer files. PeptidePrices did not inspect the facility or commission blind samples.
A registered business, with a newer public peptide service
ABN Lookup confirms the Trustee for Ozcanium Unit Trust as an active fixed unit trust from July 13, 2021, with Ozcanium Analytics registered as its business name on July 13, 2026. Its listed main business postcode is NSW 2027. These dates establish registration history; they do not date the start of peptide analysis. The lab introduced its Sydney peptide-testing service publicly on May 1, 2026, and its LinkedIn profile gives a self-reported founding year of 2024.
The report analyst is Ibrahim A. Ozcan, named as lead chemist, with Zein S. Sabini named as compiler. Their signatures make the inspected files attributable. The public profile associates Ozcan with UNSW and Ozcanium Chemical Supplies; a university affiliation is not university accreditation of this commercial service. A separate August 2026 Ozcanium Pty Ltd registration uses another ABN. The operative identity for the checked reports remains the trust ABN printed on them.
Two complete reports provide real document-level evidence
PeptidePrices checked OZ-HPLCMS-96FF and OZ-HPLCMS-CA0X for Ultima's Retatrutide 10 mg and 20 mg samples. Both were analysed on September 24, 2026. The official UUID records returned Verified with the matching code, sample, lot and date on October 9; the retained complete PDFs matched the supplier's two-page files.
The 10 mg report records 99.30% purity and 9.65 mg content; the 20 mg report records 99.28% and 20.70 mg. Each first page supplies a UPLC-UV trace and integrated peak table. Each second page explicitly assigns Retatrutide and confirms Q1 1184 → Q3 397 m/z under the printed MRM settings, alongside three SIM channels and a collected mass spectrum. These identity pages add material evidence that is lost in a first-page screenshot.
Read purity, identity and content separately
The peak tables put the assigned Retatrutide peak at 99.298% and 99.277% of integrated area, consistent with the rounded purity figures. The reports explicitly exclude salts and sugars from that peak list. Read the result as chromatographic area purity under the method, rather than the fraction of all material in the container that is peptide.
The website describes milligram content by in-house calibration and a Shimadzu LCMS-8030 workflow. The checked reports state net-content values but omit the underlying calibration curve, standard traceability, recovery data and uncertainty. Their mass-transition and monitored-ion evidence support the issuer's identity assignment, while independent reproduction would require the complete method and raw acquisitions. Neither checked sample includes an endotoxin, sterility or elemental-impurity panel.
External assurance remains the main gap
An active NATA directory search for Ozcanium returned zero results on October 9. The reviewed reports and official pages provided no current accreditation number or peptide-specific scope. The public Our Research page explains chromatography and mass-based confirmation, but it is educational method prose rather than a peptide validation dossier or proficiency study.
For a stronger technical assessment, request the applicable standard certificate and scope if accredited, reference-standard documentation, validation of selectivity and recovery, calibration and uncertainty, suitability controls for the sample matrix, and independent comparison results. The public evidence presently supports a functioning report service with inspectable analytical outputs; it does not supply that external performance record.
Current prices, sample selection and turnaround
The live service page checked October 9 lists the identity, purity and content package at A$400 excluding GST per suitable sample for one to four samples (A$440 including GST). It lists endotoxin at A$285 excluding GST, an additional same-batch vial comparison at A$250, and Common GLP-1 Blind Testing at A$600. Volume pricing depends on the test and number ordered; confirm the selected scope before sending material.
The peptide page estimates 4–10 business days from payment, receipt and completed intake checks. This is the advertised estimate, not PeptidePrices' measured turnaround. The blind service is a lab-approved request without a nominated GLP-1 analogue; it should not be confused with an independently purchased, blinded retail sampling study. Ozcanium's terms require a sampling plan and multiple independently selected units when batch consistency is the question.
Customer experience, corrections and commercial relationships
A Peptide Hub Australia customer account describes repeated testing, an initial communication delay and later improvement. Suppliers including Pepper Research and Platinum Peptides also publish Ozcanium testing claims or reports. These are customer and supplier accounts, rather than a controlled competence assessment or a verified aggregate of all clients.
In June 2026 forum discussion, a user raised report-error and service complaints. Ozcan's response says a small number of known report errors were corrected and asks for report-specific concerns with supporting files. This review did not establish the disputed originals or a complete correction history. The current terms explicitly allow amendment, supersession or withdrawal and make the newest issued version controlling; recheck the official file when relying on an older copy.
Ozcanium advertises an affiliate programme paying A$25 on qualifying referred orders and partner benefits for eligible testing. Its rules require disclosure and prohibit misleading reviews. That creates an incentive for referral recommendations and belongs in any assessment of an endorsement. Ozcan also publicly identifies with Ozcanium Chemical Supplies. The reviewed evidence does not establish that the laboratory sells the peptide samples it tested; ownership disclosures and the actual commissioning relationship should be checked for each claim of independence.
Use the current official record and the whole PDF
Copy the report ID into the official verifier or follow its exact report-specific UUID link. A functioning record shows a code, sample, status, report date and PDF download. Compare the full original, including identity pages, lots, client and reported measurements; a valid code alone does not authenticate a separately edited screenshot.
Keep a file-loading failure separate from a missing report. Verification establishes issuance, while the certificate and custody record establish what was submitted. Ozcanium's terms require the report to be read as a whole and limit its findings to that sample. Its retained-sample period is described as limited without a fixed duration, so arrange re-analysis and retention requirements directly before commissioning work.